Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma.

Abstract excerpt

There have been many recent advances in melanoma therapy. While 50% of melanomas have a BRAF mutation and are a target for BRAF inhibitors, the remaining 50% are BRAF wild-type. Immune checkpoint inhibitors targeting PD-1, cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and lymphocyte activated gene-3 (Lag-3) are all approved for the treatment of patients with advanced BRAF wild-type melanoma; however,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Immune Checkpoint Inhibitors
• Share to Immunotherapy
• Share to Lymphocytes, Tumor-Infiltrating